Last updated: September 7, 2026
Nirsevimab-alip, marketed as Beyfortus, is the leading long-acting monoclonal antibody for prevention of respiratory syncytial virus lower respiratory tract disease in infants. Sanofi and AstraZeneca reported rapid commercial expansion after the 2023 launch, with sales rising from approximately €0.5 billion in 2023 to roughly €1.5 billion in 2024. The product’s main growth drivers are broad infant eligibility, one-dose seasonal protection, improved supply, and adoption across national immunization programs. Its principal commercial risks are seasonal demand, government pricing, competition from maternal RSV vaccination, and the eventual entry of biosimilar antibodies.
What is nirsevimab-alip and how does it generate revenue?
Nirsevimab-alip is a recombinant human IgG1κ monoclonal antibody that targets the prefusion F protein of RSV. Unlike a conventional vaccine, it provides passive immunity and is administered directly to the infant. The antibody has an extended half-life that supports protection through an RSV season after one injection.
The product is sold under the Beyfortus brand. AstraZeneca developed the antibody and partnered with Sanofi for development, manufacturing, and commercialization. Sanofi leads commercialization in major markets, while AstraZeneca retains economic participation through the collaboration agreement.
| Product attribute |
Commercial position |
| Active ingredient |
Nirsevimab-alip |
| Brand |
Beyfortus |
| Drug type |
Long-acting monoclonal antibody |
| Primary use |
Prevention of RSV lower respiratory tract disease in infants |
| U.S. approval |
July 17, 2023 |
| U.S. dosage |
50 mg or 100 mg based on infant weight; 200 mg for certain high-risk children |
| Administration |
Single intramuscular dose per RSV season |
| Lead companies |
Sanofi and AstraZeneca |
| Primary alternatives |
Maternal RSV vaccination, palivizumab for selected high-risk infants |
| U.S. reference-product exclusivity |
Approximately through July 17, 2035, subject to applicable regulatory extensions |
The product’s economic model differs from chronic biologics. Revenue is concentrated around the annual RSV season and depends on birth cohorts, seasonal epidemiology, public-health policy, and procurement timing.
How large is the nirsevimab-alip market?
The addressable market is substantially larger than the historical market for palivizumab because nirsevimab is recommended for broad infant populations rather than only the highest-risk children.
In the United States, the Centers for Disease Control and Prevention recommends nirsevimab for infants younger than eight months entering their first RSV season when maternal vaccination is absent, unknown, or insufficiently timed. Certain children aged eight through 19 months who face an increased risk of severe RSV disease may receive nirsevimab before a second season.[1]
The U.S. market is divided into two principal channels:
- The Vaccines for Children program and Medicaid, which cover a large share of eligible births.
- Commercial insurance and private-provider administration.
This structure creates significant unit volume but also places pricing pressure on the manufacturer. Public-sector purchasing can reduce net price relative to the private-sector list price.
What is the U.S. price of Beyfortus?
The initial U.S. private-sector list price was approximately $495 per dose for both the 50 mg and 100 mg presentations. Public-sector pricing through the Vaccines for Children program is lower.[2] The commercial value per protected infant is therefore determined by net price, payer mix, administration economics, and the proportion of eligible infants who receive treatment.
A broad infant recommendation creates greater volume than palivizumab, but it also makes the product dependent on government reimbursement and public procurement. The result is a high-volume, lower-margin profile compared with specialty biologics administered to small high-risk populations.
What are the reported sales and financial trajectory for nirsevimab-alip?
Sanofi reported Beyfortus sales of approximately €547 million in 2023, its first commercial year. Sales accelerated in 2024 as the product benefited from broader availability, improved distribution, and increased uptake in the United States and Europe.[3][4]
| Fiscal year |
Reported or publicly disclosed sales position |
Main commercial driver |
| 2022 |
Pre-commercial |
Regulatory approvals and launch preparation |
| 2023 |
Approximately €547 million |
Initial European and U.S. launch; supply constraints in the United States |
| 2024 |
Approximately €1.5 billion |
Improved supply, wider U.S. access, stronger public-health adoption |
| 2025 onward |
Growth depends on season, pricing, and competitive mix |
Infant coverage expansion and maternal-vaccine substitution risk |
The 2023 launch was constrained by supply shortages in the United States. The CDC issued allocation guidance during the 2023-2024 RSV season, prioritizing the 100 mg dose for infants at the highest risk and limiting some use of the 50 mg dose.[5] Those constraints suppressed near-term revenue and delayed broad physician access.
The 2024 trajectory improved materially. Sanofi and AstraZeneca expanded supply, and the U.S. market moved closer to a routine seasonal immunization model. The largest incremental revenue opportunity is not a higher price. It is wider penetration across eligible birth cohorts.
How is revenue divided between Sanofi and AstraZeneca?
The companies have not disclosed a simple public revenue split that allows investors to treat Beyfortus sales as equivalent to Sanofi product revenue or AstraZeneca product revenue. Their agreement includes different economic mechanisms by geography, including collaboration economics, manufacturing payments, royalties, and profit participation.
Sanofi reports Beyfortus product sales in its financial disclosures. AstraZeneca’s economic benefit is reflected through alliance-related revenue and other collaboration income rather than necessarily through equivalent reported product sales. Investors should therefore avoid adding Sanofi and AstraZeneca reported figures without eliminating intercompany or alliance components.
What drives nirsevimab-alip demand?
The main demand drivers are epidemiological and policy-related rather than prescriber preference alone.
Infant birth cohorts
Each RSV season creates a new target population. In the United States, approximately 3.5 million births occur annually, creating a large recurring market. The number of infants eligible for treatment changes with maternal-vaccine uptake and public-health recommendations.
One-dose administration
Nirsevimab eliminates the monthly dosing burden associated with palivizumab. This improves hospital, pediatric, and pharmacy logistics and increases the feasibility of population-level protection.
Public-health programs
National immunization recommendations are central to sales. Spain, France, the United Kingdom, the United States, and other jurisdictions have adopted or evaluated broad infant immunization strategies. Public procurement can rapidly expand volume, but tenders may compress net price.
RSV season severity
RSV incidence varies by season and geography. A severe season can accelerate demand and improve provider acceptance. A mild season can reduce doses administered and cause inventory management problems.
Hospital and birth-setting administration
Administration before discharge from a maternity hospital can improve coverage. This model is operationally attractive but requires coordinated procurement, cold-chain management, billing, and documentation.
How does Beyfortus compare with maternal RSV vaccination?
Maternal vaccination and infant antibody prophylaxis are complementary but competing strategies in some cases.
Pfizer’s Abrysvo is approved in the United States for administration during pregnancy to protect newborns against RSV-associated lower respiratory tract disease. The maternal-vaccine strategy transfers protection through placental antibodies, while nirsevimab provides direct passive immunity to the infant.[6]
| Factor |
Nirsevimab-alip |
Maternal RSV vaccination |
| Recipient |
Infant |
Pregnant individual |
| Protection mechanism |
Direct monoclonal antibody |
Transplacental maternal antibodies |
| Timing |
At birth or before RSV season |
During a defined pregnancy window |
| Dependence on prenatal care |
Low |
High |
| Dose schedule |
One infant dose per season |
One maternal dose during pregnancy |
| Commercial risk |
Broad infant uptake |
Maternal acceptance and prenatal coverage |
| Operational channel |
Hospitals, pediatric offices, public programs |
Obstetric and prenatal-care systems |
CDC guidance generally uses maternal vaccination and infant nirsevimab as alternative protection strategies for most infants, with nirsevimab favored when maternal vaccination was not received, timing was inadequate, or protection is uncertain.[1]
The two products can therefore expand the overall RSV prevention market while competing for the same infant protection outcome. Higher maternal-vaccine uptake would reduce the number of infants requiring nirsevimab. Low prenatal vaccination rates, delayed prenatal care, and uncertainty about maternal vaccination status support nirsevimab demand.
What is the FDA regulatory status of Beyfortus?
The FDA approved Beyfortus on July 17, 2023, under Biologics License Application 761328 for prevention of RSV lower respiratory tract disease in neonates and infants entering their first RSV season, and in certain children entering their second season.[7]
The product is not a traditional small-molecule drug. It is regulated as a biologic, and its competitive pathway is biosimilar development under the Public Health Service Act.
The principal U.S. regulatory milestones are:
| Milestone |
Date |
| FDA approval |
July 17, 2023 |
| First full U.S. RSV season after approval |
2023-2024 |
| CDC allocation intervention |
October 2023 |
| Expanded commercial availability |
2024 RSV season |
What patents and exclusivity protect nirsevimab-alip?
Beyfortus does not have an Orange Book listing because the Orange Book is principally used for approved small-molecule drug products. Biologic patent and exclusivity analysis relies on the FDA Purple Book, patent databases, regulatory exclusivity rules, and litigation records.
The FDA grants a reference biologic 12 years of exclusivity before a biosimilar may be licensed based solely on the reference product’s data package. For Beyfortus, that period begins on the date of first licensure, July 17, 2023, and generally runs to July 17, 2035.[8]
The commercial patent estate can extend beyond or overlap with this period through claims covering:
- Nirsevimab antibody sequences and variants.
- Antibody binding to the RSV prefusion F protein.
- Formulations and stabilizers.
- Manufacturing cell lines and purification processes.
- Dosing regimens for infants and high-risk children.
- Use in preventing RSV lower respiratory tract disease.
Patent term depends on individual filing dates, patent-term adjustment, patent-term extension, terminal disclaimers, and claim scope. Unlike a small-molecule product, the absence of an Orange Book patent listing means there is no single public Orange Book date that defines generic entry.
Are there Paragraph IV challenges to nirsevimab?
Paragraph IV certifications apply to abbreviated new drug applications for small-molecule products listed in the Orange Book. They do not provide the standard challenge mechanism for a biologic such as nirsevimab-alip.
A future competitor would more likely pursue a biosimilar under the Public Health Service Act or develop a separate RSV antibody under a full biologics application. Biosimilar litigation could involve patent dance disclosures, infringement claims, validity challenges, and injunction requests. No publicly established nirsevimab biosimilar launch pathway has displaced the reference product’s regulatory exclusivity.
How strong is the nirsevimab commercial and competitive position?
Beyfortus has a strong near-term commercial position because it combines broad eligibility with a single-dose regimen and first-mover status in population-scale infant RSV prevention. Its main vulnerabilities are different from those of a conventional specialty biologic.
| Strength |
Risk |
| One-dose seasonal protection |
Annual seasonality |
| Broad infant recommendation |
Public-payer pricing pressure |
| Strong clinical and policy adoption |
Maternal RSV vaccine substitution |
| Limited direct infant-antibody competition |
Supply and inventory volatility |
| Long biologic exclusivity period |
Future biosimilar and next-generation antibody risk |
| Established Sanofi and AstraZeneca infrastructure |
Dependence on national recommendations |
The most important commercial variable is coverage rate among eligible infants. Revenue can grow even if price declines, provided treatment volume expands faster than net-price erosion. Conversely, strong clinical demand will not translate into expected revenue if procurement contracts force substantial discounts.
What generic or biosimilar entry risks exist?
Near-term generic entry risk is low because nirsevimab is a biologic and cannot be copied through a conventional abbreviated new drug application. Biosimilar entry is constrained by:
- Twelve years of U.S. reference-product exclusivity.
- Antibody sequence and formulation patents.
- Complex analytical comparability requirements.
- Clinical and immunogenicity development costs.
- Seasonal manufacturing and inventory requirements.
- Limited certainty about payer substitution for preventive biologics.
A biosimilar could still emerge before all patent claims expire if it launches after regulatory exclusivity and successfully navigates patent disputes. The likely entry strategy would focus on a highly similar antibody with a competitive price and inclusion in government purchasing programs.
What is the outlook for nirsevimab-alip revenue?
The financial trajectory is likely to move through three stages.
2023: Launch and supply-constrained adoption
The first year established regulatory access and generated approximately €547 million in sales. U.S. shortages limited penetration and created reputational and operational costs.
2024: Rapid expansion
Improved supply and broader health-system integration drove sales to approximately €1.5 billion. The United States became a major incremental market, while European immunization programs continued to support recurring demand.
2025 and later: Penetration versus substitution
Future growth depends on five variables:
- The share of eligible infants receiving nirsevimab.
- Maternal RSV vaccine uptake.
- RSV season intensity.
- Net prices under government tenders.
- Expansion into additional geographies and high-risk pediatric populations.
The product can remain a multibillion-euro asset if broad infant coverage persists and maternal vaccination does not displace a large share of doses. Revenue will likely become more seasonal and policy-sensitive as the product matures.
Key Takeaways
- Nirsevimab-alip, sold as Beyfortus, is the leading long-acting monoclonal antibody for infant RSV prevention.
- Sanofi reported approximately €547 million in 2023 sales, followed by roughly €1.5 billion in 2024.
- The U.S. market expanded rapidly after 2023 supply constraints were addressed.
- The product’s strongest commercial attributes are one-dose administration, broad infant eligibility, and public-health adoption.
- Maternal RSV vaccination is the principal near-term demand substitute.
- Beyfortus is a biologic, so Paragraph IV generic challenges and Orange Book listings do not apply in the usual manner.
- U.S. reference-product exclusivity generally runs through July 17, 2035.
- Long-term revenue depends more on infant coverage, payer pricing, maternal-vaccine uptake, and RSV season severity than on additional indications.
- Biosimilar risk is limited before the mid-2030s but could become material thereafter.
FAQs
Is nirsevimab-alip a vaccine?
No. Nirsevimab-alip is a long-acting monoclonal antibody that provides passive immunity directly to the infant. It is administered after birth or before an RSV season.
How often is Beyfortus administered?
Beyfortus is generally administered as a single intramuscular dose for an RSV season. Dose strength depends on the infant’s weight.
Is Beyfortus covered by Medicaid?
Beyfortus is available through public-health channels, including the Vaccines for Children program, and coverage varies by eligibility, state policy, and payer arrangement.
Can an infant receive Beyfortus after maternal RSV vaccination?
Most infants do not need both forms of protection. Nirsevimab may be considered when maternal vaccination was absent, administered too late, or unlikely to provide adequate passive protection under applicable clinical guidance.
When could a nirsevimab biosimilar enter the U.S. market?
The earliest broad U.S. biosimilar opportunity is generally constrained by the 12-year reference-product exclusivity period ending in July 2035, although patent litigation and regulatory requirements would also affect launch timing.
References
-
Centers for Disease Control and Prevention. (2024). RSV immunization guidance for infants and young children. U.S. Department of Health and Human Services.
-
Centers for Disease Control and Prevention. (2023). Nirsevimab administration and pricing information. U.S. Department of Health and Human Services.
-
Sanofi. (2024). 2023 annual report. Sanofi S.A.
-
Sanofi. (2025). 2024 annual results and annual report. Sanofi S.A.
-
Centers for Disease Control and Prevention. (2023). Limited availability of nirsevimab in the United States. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023). FDA approves vaccine for pregnant individuals to prevent RSV in infants. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023). Beyfortus prescribing information and approval letter. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Reference product exclusivity and biosimilar biological products. U.S. Department of Health and Human Services.
